Webinar On-Demand: 

Cytokine Biomarkers of Inflammatory Response in COVID-19 Patients

Hosted by Sino Biological

As COVID-19 pandemic preparedness initiatives ramp up to address the current crisis, one area of focus has been the improvement of testing methods to re-open society. Here, Quanterix Chairman, CEO, and President Kevin Hrusovsky and VP of Pharma Services Dan Sikkema, PhD discuss how the ultra-sensitive SIMOA™ biomarker detection platform can be used in efforts around frontline immunological and serologic assessments of COVID-19.  

Institut Pasteur's Darragh Duffy, PhD, explains how Simoa was used to identify a unique phenotype in severe and critical COVID-19 patients, consisting of a profoundly impaired interferon (IFN) type I response characterized by no IFN-b and low IFN-a production.


Please complete the form to access the video.

By submitting this form, you agree to Quanterix’s Terms of Use and Privacy Policy.  In addition, you agree to receive information regarding Quanterix products and services.  You will be able to unsubscribe at any time.

Follow Us!